세포 및 유전자 치료 시장 거래 : 투자, M&A, 파트너십 - 2021-2025년(제3판)

Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)

US $ 7,000 ￦ 10,128,000

Online Access (Single User License)

PDF 보고서를 1분이 열람(다운로드 불가)할 수 있는 라이선스입니다. 인쇄는 1회 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,469,000

Online Access & PDF Download (Unlimited Users)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세포 및 유전자 치료(CGT) 시장은 빠르게 진화하고 있으며, 수십억 달러의 투자와 수천 건의 전략적 거래가 그 궤도를 형성하고 있습니다. 이러한 상황을 이해하고 미래의 거래 동향을 예측하는 기업은 성공에 필요한 경쟁력을 갖출 수 있습니다.

세포 및 유전자 치료(CGT) 분야는 CRISPR, 차세대 염기서열분석(NGS), 획기적인 치료제와 같은 최첨단 기술 발전에 힘입어 의료 혁신의 최전선에 있으며, 약 2,000여 개의 기업이 CGT 산업에 적극적으로 참여하고 있으며, 막대한 투자, 전략적 제휴, 획기적인 거래가 이루어지고 있습니다. 거래가 이루어지고 있습니다. 그러나 다양한 유형의 자금 조달 가능성, 규제 환경의 변화, 통합 추세 등 시장 역학의 변화로 인해 투자 전망이 달라지고 있습니다.

세포 및 유전자 치료제 시장 거래: 투자, M&A, 파트너십, 2021-2025년(제3판)은 두 차례에 걸쳐 발간되며, 2025년 2월에 발간되는 제1판은 2024년 말까지 거래된 사례를 다루고 있습니다. 제2판은 2025년 가을에 발간될 예정이며, 2025년 9월까지의 사례를 다룰 예정입니다.

CGT 시장의 금융 생태계를 심층적으로 분석하여 재생의료의 미래를 주도하는 거래에 대한 실용적인 인사이트을 제공합니다. 업계 전문가 인터뷰, 광범위한 문헌 조사, 기업 및 정부 보고서 분석 등을 통해 세포 및 유전자 치료제 시장의 투자, 인수합병, 파트너십 등 거래 동향에 대한 정보를 제공합니다.

목차

제1장 개요

제2장 벤처캐피털과 민간 자금조달

• 유동적인 VC/민간 자금조달

제3장 전략적 투자

• 세포·유전자 치료에 대한 전략적 투자

제4장 IPO, FPO, SPAC

• 북미에서는 IPO, FPO, SPAC로부터의 수익이 대부분을 차지한다.

제5장 합병과 인수(M&A)

• 평균 가치의 하락에도 불구하고 M&A 건수는 증가

제6장 기술/연구/전략적 협업

• CGT 시장에서는 다양한 협업을 볼 수 있다.

제7장 라이선싱

• 세포·유전자 치료 시장에서 라이선싱의 안정 레벨

제8장 제조와 공급망

• CGT에서 제조 및 공급망 관리 활동의 대폭적인 성장

제9장 유통과 공동 마케팅

• CGT 배포 및 공동 마케팅 계약의 개요

제10장 기타-JV, 재편, 해산, 스핀오프

• 세포·유전자 치료에 영향을 미치는 기타 거래

KSA

영문 목차

영문목차

The CGT market is evolving rapidly, with billions in investments and thousands of strategic deals shaping its trajectory. Companies that understand the landscape and anticipate future deal trends will have the competitive edge needed to thrive. Whether you are a biotech executive, investor, R&D leader, or regulatory strategist, this report provides data-driven insights to inform your next move.

TWO REPORTS FOR THE PRICE OF ONE

"Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)" is published in two installments. The first installment, released in February 2025, covers deals up to the end of 2024. The second installment will be released in Fall 2025 and will cover deals through September 2025. Customers who purchase this third edition will receive both installments. The report covers deals including financing, funding, partnering, M&A, tech transfers, IPOs/SPACs, and other deals.

"Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)" is also the companion to another 2025 Kalorama Information report, "Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts 2024-2030 (4th Edition) ", which will be released in Spring 2025. The report focuses on cell and gene therapy for disease segments including oncology, neurology, musculoskeletal, dermatology, cardiology/non-oncology blood, and more. "Cell and Gene Therapy Market Dynamics by Disease Type, 4th Edition" will be available for a separate price.

The cell and gene therapy (CGT) field is at the forefront of medical innovation, fueled by cutting-edge advancements in CRISPR, next-generation sequencing (NGS), and breakthrough therapeutics. With around 2,000 companies actively engaged in the CGT industry, the sector has witnessed significant volumes of investments, strategic collaborations, and groundbreaking deals. However, shifting market dynamics-including fluctuating availability of funding of different types, evolving regulatory landscapes, and consolidation trends-have reshaped the investment outlook.

Kalorama Information's new report, "Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)", delivers an unparalleled deep dive into the CGT market's financial ecosystem, offering actionable insights into the deals that are driving the future of regenerative medicine.

Report Features

• Investment & Funding Trends - Track quarterly funding fluctuations from Q1 2021 to Q4 2024, with a focus on venture capital, private equity, and public offerings.
• M&A and Strategic Partnerships - Understand how acquisitions, licensing agreements, manufacturing deals, and co-marketing partnerships are shaping the competitive landscape.
• Regional Market Insights - Gain a global perspective on deal activity across North America, Europe, Asia-Pacific, and emerging markets.
• Top Players & Deal-Making Trends - Identify the industry's most active investors, biotech startups, and pharmaceutical leaders driving CGT growth.
• Regulatory & Market Challenges - Explore how regulatory shifts, reimbursement strategies, and supply chain dynamics impact CGT deal-making.

In addition, the following is just some of the information in this report:

• Quarterly Funding Amounts Q1 2021- Q4 2024 by Type and Region
• Specific details of 2,000+ CGT Deals from 2021 through 2024
• Venture Capital/Private Funding Round Amounts, By Quarter
• Monthly VC/Private Funding, by Seed/ Angel, Series A/ B/ C/ D or PIPE/ direct offering
• Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
• Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture
• Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
• Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)

Methodology

The report's insights are derived from a blend of primary and secondary research, including interviews with industry professionals, comprehensive literature reviews, and analysis of company and government reports.

Table of Contents

Chapter 1: Executive Summary

• Introduction
• 2024 Investments
  • Figure 1-1: Total Deals per Month, Apr 2021-Dec 2024 (count)
  • Figure 1-2: Total Deals per Month, by Type, Apr 2021-Dec 2024 (count) [IPO/FPO/SPAC, VC/Private, All Other Deals]
• Quarterly Funding Amounts
  • Table 1-1: Total Quarterly Funding and Shares, by Type, 2024 ($ million) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Table 1-2: Total Quarterly Funding, by Type, 2023 ($ million) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Table 1-3: Total Quarterly Funding, by Type, 2022 ($ million) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Table 1-4: Total Quarterly Funding and Shares, by Type, 2021 ($ million) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Figure 1-3: Total Quarterly Investment/Funding, Q1 2021-Q4 2024 ($ million)
  • Figure 1-4: Total Quarterly Funding, by Type, Q1 2021-Q4 2024 ($ million) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
• Quarterly Funding Category Shares, Q1 2021 Through Q4 2024
  • Table 1-5: Total Quarterly Funding Share, by Type, 2024 (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Table 1-6: Total Quarterly Funding Share, by Type, 2023 (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Table 1-7: Total Quarterly Funding Share, by Type, 2022 (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Table 1-8: Total Quarterly Funding Share, by Type, 2021 (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Figure 1-5: Total Quarterly Funding Share, by Type, Q1 2021-Q4 2024 (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Figure 1-6: 2024 Funding Share, by Type of Funding (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Figure 1-7: 2023 Funding Share, by Type of Funding (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Figure 1-8: 2022 Funding Share, by Type of Funding (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
  • Figure 1-9: 2021 Funding Share, by Type of Funding (%) [Collaboration Payments, IPO/FPO, M&A, SPAC, Strategic Investments, VC/Private]
• Quarterly Deal Counts by Category, Q1 2021-Q4 2024
  • Table 1-9: Quarterly Count of Deals, By 2024 Quarter, By Category (total number) (%) [Acquisition, Merger, Strategic Investment; Conclude/Terminate Deal; Distribution, Co-Marketing; Licensing; Manufacturing, Supply Chain; Public Offering/SPAC; Spinout, Restructure, Technology/Research/Strategic Collaboration; Venture Capital/Private Investment]
  • Table 1-10: Quarterly Count of Deals, By 2023 Quarter, By Category (total number) (%) [Acquisition, Merger, Strategic Investment; Conclude/Terminate Deal; Distribution, Co-Marketing; Licensing; Manufacturing, Supply Chain; Public Offering/SPAC; Spinout, Restructure, Technology/Research/Strategic Collaboration; Venture Capital/Private Investment]
  • Table 1-11: Quarterly Count of Deals, by 2022 Quarter, By Category (total number) (%) [Acquisition, Merger, Strategic Investment; Conclude/Terminate Deal; Distribution, Co-Marketing; Licensing; Joint Venture; Manufacturing, Supply Chain; Public Offering/SPAC; Spinout, Restructure, Technology/Research/Strategic Collaboration; Venture Capital/Private Investment]
  • Table 1-12: Quarterly Count of Deals, by 2021 Quarter, By Category (total number) (%) [Acquisition, Merger, Strategic Investment; Conclude/Terminate Deal; Distribution, Co-Marketing; Licensing; Joint Venture; Manufacturing, Supply Chain; Public Offering/SPAC; Spinout, Restructure, Technology/Research/Strategic Collaboration; Venture Capital/Private Investment]
  • Table 1-13: Yearly Shares of Number of Deals, By Category, 2021-2024 (%) [Acquisition, Merger, Strategic Investment; Conclude/Terminate Deal; Distribution, Co-Marketing; Licensing; Joint Venture; Manufacturing, Supply Chain; Public Offering/SPAC; Spinout, Restructure, Technology/Research/Strategic Collaboration; Venture Capital/Private Investment]
• Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/Co-Marketing Highlight Activity in Cell and Gene Therapy
  • Figure 1-10: Yearly Shares of Number of Deals, By Category, 2021-2024 (%) [Acquisition, Merger, Strategic Investment; Conclude/Terminate Deal; Distribution, Co-Marketing; Joint Venture; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Technology/Research/Strategic Collaboration; Spinout, Restructure; Venture Capital/Private Investment]
  • Figure 1-11: Most Frequent Types of Deals by Quarter, by Category, 2021-2024 (Total Number) [Acquisition, Merger, Strategic Investment; Conclude/Terminate Deal; Distribution, Co-Marketing; Joint Venture; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Technology/Research/Strategic Collaboration; Spinout, Restructure; Venture Capital/Private Investment]
• A Look at Less Frequent CGT Deal Types
  • Figure 1-12: Lower Frequency Deal Types, by Quarter, by Category, Q1 2021-Q4 2024 (Total Number) [Conclude/Terminate Deal; Distribution, Co-Marketing; Joint Venture; Spinout, Restructure]
  • Figure 1-13: Merger/Acquisition Amount, by Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 1-14: Venture Capital/Private Funding Round Amount, by Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 1-15: IPO/FPO Amount, by Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 1-16: SPAC Portion Amount, by Year, 2021- 2024 ($ million)
• Most Active Companies
  • Table 1-14: Most Active Companies in Cell and Gene Therapy Deals and Collaborations, Overall, 2021-2024 (Total Number) [Astellas Pharma, Bayer, Bristol Myers Squibb, CGT Catapult, Charles River Laboratories, Cytiva (Danaher), Eli Lilly, ERS Genomics, Ginkgo Bioworks, Janssen, Lonza, MaxCyte, Novartis, Oxford Biomedica, Pfizer, Resilience, Sanofi, Sartorius, Takeda Pharmaceutical, Thermo, Vertex Pharmaceuticals]
  • Figure 1-17: Most Active Companies in CGT Deals, Collaborations, Overall 2021-2024 [Astellas Pharma, Bayer, Bristol Myers Squibb, CGT Catapult, Charles River Laboratories, Cytiva (Danaher), Eli Lilly, ERS Genomics, Ginkgo Bioworks, Janssen, Lonza, MaxCyte, Novartis, OXB (Oxford Biomedica), Pfizer, Resilience, Sanofi, Sartorius, Takeda Pharmaceutical, Thermo, Vertex Pharmaceuticals]

Chapter 2: Venture Capital & Private Funding

• VC/Private Funding in Flux
  • Figure 2-1: Total Number of Private Investment/VC Rounds by Month, Jan 2021-Dec 2024 (count)
  • Figure 2-2: Average VC/Private Funding Round Amount, By Quarter Q1 2021-Q4 2024 ($ million)
  • Table 2-1: Regional Venture Capital/Private Funding, by Quarter Q1 2021-Q4 2024 ($ million) (%) [APAC, Europe, North America, Rest of World]
  • Figure 2-3: Quarterly Venture Capital/Private Total Funding, Q1 2021- Q4 2024, by Region ($ million) [APAC, Europe, North America, Rest of World]
  • Table 2-2: Regional Venture Capital/Private Funding Shares, by Quarter, Q1 2021 Q1 2024 (%) [APAC, Europe, North America, Rest of World]
  • Figure 2-4: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021-Q4 2024 (%) [APAC, Europe, North America, Rest of World]
  • Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 2-6: Scaled Venture Capital/Private Funding Round Amounts, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 2-7: Total Number of Angel/Pre-Seed/Seed Funding Rounds, By Month, Feb 2021-Dec 2024 (count)
  • Figure 2-8: Total Funding from Angel/Pre-Seed/Seed Funding Rounds, By Month, Feb 2021-Dec 2024 ($ million)
  • Figure 2-9: Total Number of Series A Funding Rounds, By Month, Dec 2020-Dec 2024 (count)
  • Figure 2-10: Total Funding Raised from Series A Funding Rounds, By Month, Dec 2020-Dec 2024 ($ million)
  • Figure 2-11: Total Number of Series B Funding Rounds, By Month, Dec 2020-Jan 2025 (count)
  • Figure 2-12: Total Funding Raised from Series B Funding Rounds, By Month, Dec 2020-Nov 2024 ($ million)
  • Figure 2-13: Total Number of Series C Funding Rounds, By Month, Jan 2021-Jan 2025 (count)
  • Figure 2-14: Total Funding Raised from Series C Funding Rounds, By Month, Dec 2020-Jan 2025 ($ million)
  • Figure 2-15: Total Number of Series D Funding Rounds, By Month, Jan 2021-Sep 2024 (count)
  • Figure 2-16: Total Funding Raised from Series D Funding Rounds, By Month, Jan 2021-Sep 2024 ($ million)
  • Figure 2-17: Total Number of PIPE/Direct Offering, By Month, Jan 2021-Dec 2024 (count)
  • Figure 2-18: Total Funding Raised from PIPE/Direct Offering, By Month, Dec 2020-Dec 2024 ($ million)
  • Figure 2-19: Total Number of Unspecified/Other Rounds, By Month, Jan 2021-Dec 2024 (count)
  • Figure 2-20: Total Funding Raised from Unspecified/Other Funding Rounds, By Month, Jan 2021-Dec 2024 ($ million)
  • Table 2-3: Venture Capital/Private Fundraising Deals, Q4 2024
  • Table 2-4: Venture Capital/Private Fundraising Deals, Q3 2024
  • Table 2-5: Venture Capital/Private Fundraising Deals, Q2 2024
  • Table 2-6: Venture Capital/Private Fundraising Deals, Q1 2024
  • Table 2-7: Venture Capital/Private Fundraising Deals, Q4 2023
  • Table 2-8: Venture Capital/Private Fundraising Deals, Q3 2023
  • Table 2-9: Venture Capital/Private Fundraising Deals, Q2 2023
  • Table 2-10: Venture Capital/Private Fundraising Deals, Q1 2023
  • Table 2-11: Venture Capital/Private Fundraising Deals, Q4 2022
  • Table 2-12: Venture Capital/Private Fundraising Deals, Q3 2022
  • Table 2-13: Venture Capital/Private Fundraising Deals, Q2 2022
  • Table 2-14: Venture Capital/Private Fundraising Deals, Q1 2022

Chapter 3: Strategic Investments

• Strategic Investments in Cell and Gene Therapy
  • Figure 3-1: Total Number of Strategic Investments, By Quarter, Q1 2021-Q4 2024 (count)
  • Figure 3-2: Average Strategic Investment Amount, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 3-3: Total Strategic Investment Amount, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Table 3-1: Strategic Investment Total Amounts, Counts, and Averages by Quarter, Q1 2021-Q4 2024 ($ million)
  • Table 3-2: Strategic Investments, January 2021-Dec 2024
  • Table 3-3: Most Active Companies in Acquisition/Merger/Strategic Investment, 2021-2024 [AstraZeneca, Bayer, bluebird bio, Bristol Myers Squibb, Catalent, Charles River Laboratories, Eli Lilly, Ginkgo Bioworks, J&J, Merck, Novartis, Novo Nordisk, Pfizer, Polyplus-transfection, Resilience, Sanofi, Sartorius, Takeda Pharmaceutical]
  • Figure 3-4: Most Active Companies in Acquisition/Merger/Strategic Investment, 2021-2024 [AstraZeneca, Bayer, bluebird bio, Bristol Myers Squibb, Catalent, Charles River Laboratories, Eli Lilly, Ginkgo Bioworks, J&J, Merck, Novartis, Novo Nordisk, Pfizer, Polyplus-transfection, Resilience, Sanofi, Sartorius, Takeda Pharmaceutical]

Chapter 4: IPOs, FPOs, & SPACs

• North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
  • Figure 4-1: Total Number of IPOs/FPOs, By Month, Jan 2021-Dec 2024 (count)
  • Figure 4-2: Average IPO/FPO Proceeds, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Table 4-1: Quarterly IPO/FPO Total Funding, by Region, Q1 2021-Q4 2024 ($ million) [APAC, Europe, North America]
  • Figure 4-3: Total IPO/FPO Funding, By Quarter, by Region, Q1 2021-Q4 2024 ($ million) [APAC, Europe, North America]
  • Table 4-2: Regional IPO/ FPO Funding Shares, by Quarter, Q1 2021-Q4 2024 (%) [APAC, Europe, North America]
  • Figure 4-4: Regional IPO/FPO Funding Shares, By Quarter, Q1 2021-Q4 2024 (%) [APAC, Europe, North America]
  • Figure 4-5: IPO/FPO Amounts, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Table 4-3: Quarterly SPAC Funding Portion, Q1 2021-Q4 2024 ($ million)
  • Figure 4-6: Quarterly SPAC Funding Portion Total and Average, Q1 2021-Q4 2024 ($ million)
  • Table 4-4: IPO/FPO Deals, Q4 2024
  • Table 4-5: IPO/FPO Deals, Q3 2024
  • Table 4-6: IPO/FPO Deals, Q2 2024
  • Table 4-7: IPO/FPO Deals, Q1 2024
  • Table 4-8: IPO/FPO Deals, Q4 2023
  • Table 4-9: IPO/FPO Deals, Q3 2023
  • Table 4-10: IPO/FPO Deals, Q2 2023
  • Table 4-11: IPO/FPO Deals, Q1 2023
  • Table 4-12: IPO/FPO Deals, Q4 2022
  • Table 4-13: IPO/FPO Deals, Q3 2022
  • Table 4-14: IPO/FPO Deals, Q2 2022
  • Table 4-15: IPO/FPO Deals, Q1 2022
  • Table 4-16: SPAC Portion, Q1 2021-Q4 2024 ($ million)
  • Figure 4-7: SPAC Portion Amount, by Year, 2021-2024 ($ million)

Chapter 5: Mergers & Acquisitions (M&A)

• Growing Numbers of M&A, Despite Lower Average Value
  • Figure 5-1: Total Number of Mergers and Acquisitions, By Month, Jan 2021-Dec 2024 (count, 3-mo avg)
  • Figure 5-2: Average Merger/Acquisition Amount, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q4 2024 ($ million) (Total count)
  • Figure 5-3: Merger/Acquisition Transactions Global Total, By Quarter, Q1 2022-Q4 2024 ($ million)
  • Figure 5-4: Merger/Acquisition Amounts, by Quarter, Q1 2021-Q4 2024 ($ million)
  • Table 5-2: Mergers and Acquisitions Announcements, Q4 2024 ($ million)
  • Table 5-3: Mergers and Acquisitions Announcements, Q3 2024 ($ million)
  • Table 5-4: Mergers and Acquisitions Announcements, Q2 2024 ($ million)
  • Table 5-5: Mergers and Acquisitions Announcements, Q1 2024 ($ million)
  • Table 5-6: Mergers and Acquisitions Announcements, Q4 2023 ($ million)
  • Table 5-7: Mergers and Acquisitions Announcements, Q3 2023 ($ million)
  • Table 5-8: Mergers and Acquisitions Announcements, Q2 2023 ($ million)
  • Table 5-9: Mergers and Acquisitions Announcements, Q1 2023 ($ million)
  • Table 5-10: Mergers and Acquisitions, Q4 2022 ($ million)
  • Table 5-11: Mergers and Acquisitions, Q3 2022 ($ million)
  • Table 5-12: Mergers and Acquisitions, Q2 2022 ($ million)
  • Table 5-13: Mergers and Acquisitions, Q1 2022 ($ million)
  • Table 5-14: Most Active Companies in Acquisition/Merger/Strategic Investment, 2021-2024 (count) [AstraZeneca, Bayer, bluebird bio, Bristol Myers Squibb, Catalent, Charles River Laboratories, Eli Lilly, Ginkgo Bioworks, J&J, Merck, Novartis, Novo Nordisk, Pfizer, Polyplus-transfection, Resilience, Sanofi, Sartorius, Takeda Pharmaceutical]
  • Figure 5-5: Most Active Companies in Acquisition/Merger/Strategic Investment, 2021-2024 [AstraZeneca, Bayer, bluebird bio, Bristol Myers Squibb, Catalent, Charles River Laboratories, Eli Lilly, Ginkgo Bioworks, J&J, Merck, Novartis, Novo Nordisk, Pfizer, Polyplus-transfection, Resilience, Sanofi, Sartorius, Takeda Pharmaceutical]

Chapter 6: Technology/Research/Strategic Collaborations

• CGT Market Sees a Broad Variety of Collaborations
  • Figure 6-1: Total Number of Tech/ Research/Strategic Collaborations, By Month, Jan 2021-Dec 2024 (count)
  • Figure 6-2: Total Number of Collaborations with Upfront and/or Milestone Payments, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Table 6-1: Collaboration Upfront and Future/ Milestone Payments, Counts, Averages, Q1 2021-Q1 2024 ($ million) (count)
  • Figure 6-3: Average Collaboration Upfront Payment, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 6-4: Research Collaboration Upfront Payments Total, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 6-5: Average Collaboration Future/Milestone Payments, By Quarter, Q1 2021-Q4 2024 ($ million)
  • Figure 6-6: Total Collaboration Future/Milestone Payments, By Quarter, Q2 2021-Q4 2024 ($ million)
  • Table 6-2: Technology/Research/Strategic Collaboration Deals, Q4 2024
  • Table 6-3: Technology/Research/Strategic Collaboration Deals, Q3 2024
  • Table 6-4: Technology/Research/Strategic Collaboration Deals, Q2 2024
  • Table 6-5: Technology/Research/Strategic Collaboration Deals, Q1 2024
  • Table 6-6: Technology/Research/Strategic Collaboration Deals, Q4 2023
  • Table 6-7: Technology/Research/Strategic Collaboration Deals, Q3 2023
  • Table 6-8: Technology/Research/Strategic Collaboration Deals, Q2 2023
  • Table 6-9: Technology/Research/Strategic Collaboration Deals, Q1 2022-Q1 2023
  • Table 6-10: Most Active in Research/Strategic Collaborations, 2021-2024 (count) [Astellas Pharma, BioCentriq, Bristol Myers Squibb, CGT Catapult, Charles River Laboratories, GenScript, Ginkgo Bioworks, Merck, Moderna, Novo Nordisk, Resilience, Roche, Takeda Pharmaceutical, Univ. of Pennsylvania, Vertex Pharmaceuticals]
  • Figure 6-7: Most Active in Research/ Strategic Collaborations, 2021-2024 (count) [Astellas Pharma, BioCentriq, Bristol Myers Squibb, CGT Catapult, Charles River Laboratories, GenScript, Ginkgo Bioworks, Merck, Moderna, Novo Nordisk, Resilience, Roche, Takeda Pharmaceutical, Univ. of Pennsylvania, Vertex Pharmaceuticals]

Chapter 7: Licensing

• Stable Levels of Licensing in the Cell and Gene Therapy Market
  • Figure 7-1: Total Number of Licensing Deals, By Month, Jan 2021-Dec 2024 (count)
  • Table 7-1: Licensing Deals, Q4 2024
  • Table 7-2: Licensing Deals, Q3 2024
  • Table 7-3: Licensing Deals, Q2 2024
  • Table 7-4: Licensing Deals, Q1 2024
  • Table 7-5: Licensing Deals, Q4 2023
  • Table 7-6: Licensing Deals, Q3 2023
  • Table 7-7: Licensing Deals, Q2 2023
  • Table 7-8: Licensing Deals, Q1 2022-Q1 2023
  • Table 7-9: Most Active Companies in Licensing Deals, 2021-2024 (count) [Astellas Pharma, Bristol Myers Squibb, ERS Genomics, Eterna Therapeutics, Janssen, MaxCyte, Novartis, Novo Nordisk, Oxford Biomedica, Pfizer, Precision BioSciences, Takeda Pharmaceutical, Taysha Gene Therapies, Vertex Pharmaceuticals]
  • Figure 7-2: Most Active Companies in Licensing Deals, 2021- 2024 (count) [Astellas Pharma, Bristol Myers Squibb, ERS Genomics, Eterna Therapeutics, Janssen, MaxCyte, Novartis, Novo Nordisk, Oxford Biomedica, Pfizer, Precision BioSciences, Takeda Pharmaceutical, Taysha Gene Therapies, Vertex Pharmaceuticals]

Chapter 8: Manufacturing and Supply Chain

• Major Growth in Manufacturing and Supply Chain Management Activity in CGT
  • Figure 8-1: Total Number of Supply/Manufacturing Deals, By Month, Jan 2021-Dec 2024 (count)
  • Table 8-1: Manufacturing and Supply Chain Deals, Q4 2024
  • Table 8-2: Manufacturing and Supply Chain Deals, Q3 2024
  • Table 8-3: Manufacturing and Supply Chain Deals, Q2 2024
  • Table 8-4: Manufacturing and Supply Chain Deals, Q1 2024
  • Table 8-5: Manufacturing and Supply Chain Deals, Q4 2023
  • Table 8-6: Manufacturing and Supply Chain Deals, Q3 2023
  • Table 8-7: Manufacturing and Supply Chain Deals, Q2 2023
  • Table 8-8: Manufacturing and Supply Chain Deals, Q1 2022-Q1 2023
  • Table 8-9: Most Active Companies in Manufacturing/Supply Deals, 2021-2024 (count) [Andelyn Biosciences, CGT Catapult, Catalent, Center for Breakthrough Medicines, Charles River Laboratories, Cytiva (Danaher), Exothera, FUJIFILM Diosynth Biotechnologies, Forge Biologics, Lonza, Minaris Regenerative Medicine, NorthX Biologics, Novartis, Oxford Biomedica, Resilience, WuXi Advanced Therapies]
  • Figure 8-2: Most Active Companies in Manufacturing/Supply Deals, 2021-Apr 2024 (count) [Andelyn Biosciences, CGT Catapult, Catalent, Center for Breakthrough Medicines, Charles River Laboratories, Cytiva (Danaher), Exothera, FUJIFILM Diosynth Biotechnologies, Forge Biologics, Lonza, Minaris Regenerative Medicine, NorthX Biologics, Novartis, Oxford Biomedica, Resilience, WuXi Advanced Therapies]

Chapter 9: Distribution & Co-Marketing

• A Look at CGT Distribution and Co-Marketing Deals
  • Figure 9-1: Total Number of Distribution/Co-Marketing Deals, by Month, Jan 2021-Apr 2024 (count)
  • Table 9-1: Distribution & Co-Marketing Deals, Q4 2024
  • Table 9-2: Distribution & Co-Marketing Deals, Q3 2024
  • Table 9-3: Distribution & Co-Marketing Deals, Q2 2024
  • Table 9-4: Distribution & Co-Marketing Deals, Q1 2024
  • Table 9-5: Distribution & Co-Marketing Deals, Q4 2023
  • Table 9-6: Distribution & Co-Marketing Deals, Q3 2023
  • Table 9-7: Distribution & Co-Marketing Deals, Q2 2023
  • Table 9-8: Distribution & Co-Marketing Deals, Q1 2022-Q1 2024
  • Table 9-9: Most Active Companies in Co-Marketing/Distribution, 2021-2024 (count) [908 Devices, Cryoport Systems, GenScript, Germfree Laboratories, Ginkgo Bioworks, Multiply Labs, Pluristyx, RoosterBio, Sartorius, Thermo, TrakCel, Vineti]
  • Figure 9-2: Most Active Companies in Co-Marketing/Distribution Deals, 2021-2024 (count) [908 Devices, Cryoport Systems, GenScript, Germfree Laboratories, Ginkgo Bioworks, Multiply Labs, Pluristyx, RoosterBio, Sartorius, Thermo, TrakCel, Vineti]

Chapter 10: Other - JV, Restructuring, Termination, Spinoffs

• A Look at Other Types of Deals Impacting Cell and Gene Therapy
  • Figure 10-1: Total Number of JV, Restructuring, Conclusion, By Month, Jan 2021-Dec 2024 (Total count)
  • Table 10-1: Restructuring, JV, Termination, Spinoffs, January 2022-Dec 2024

관련자료